Cerebral venous thrombosis without thrombocytopenia after a single dose of COVID-19 (Ad26.COV2.S) vaccine injection: a case report

[1] Chen Y(2021)COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer Biosci Trends 15 64-73

[2] Cheng L(2021)Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 Euro Surveill 26 2100533-684

[3] Lian R(2021)Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021 MMWR Morb Mortal Wkly Rep 70 680-1884

[4] Song Z(2015)Heparin-induced thrombocytopenia N Engl J Med 373 1883-905

[5] Tian J(2003)Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance Br J Haematol 123 903-438

[6] Tran Kiem C(2021)Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation Diabetes Metab Syndr 15 102184-undefined

[7] Andronico A(2020)Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights J Stroke Cerebrovasc Dis 29 104941-undefined

[8] Bosetti P(2013)Cerebral sinus venous thrombosis J Neurosci Rural Pract 4 427-undefined

[9] Paireau J(2021)Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story Metabol Open 11 100101-undefined

[10] Alter L(2009)Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment Neurosurg Focus 27 E3-undefined

[1] Chen Y(2021)COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer Biosci Trends 15 64-73

[2] Cheng L(2021)Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 Euro Surveill 26 2100533-684

[3] Lian R(2021)Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021 MMWR Morb Mortal Wkly Rep 70 680-1884

[4] Song Z(2015)Heparin-induced thrombocytopenia N Engl J Med 373 1883-905

[5] Tian J(2003)Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance Br J Haematol 123 903-438

[6] Tran Kiem C(2021)Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation Diabetes Metab Syndr 15 102184-undefined

[7] Andronico A(2020)Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights J Stroke Cerebrovasc Dis 29 104941-undefined

[8] Bosetti P(2013)Cerebral sinus venous thrombosis J Neurosci Rural Pract 4 427-undefined

[9] Paireau J(2021)Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story Metabol Open 11 100101-undefined

[10] Alter L(2009)Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment Neurosurg Focus 27 E3-undefined